融信中國(03301.HK)尚未支付2023年6月及12月票據之到期利息
融信中國(03301.HK)公布,尚未支付2023年6月到期8.1%優先票據到期利息1,279.8萬美元及2023年12月到期7.35%優先票據到期利息1,506.75萬美元。
集團表示,考慮到集團當前流動資金狀況,集團無法保證能如期或在相關寬限期內履行上述優先票據利息及其他優先票據的償付債務。
集團希望債權人給予一定的緩衝時間去解決目前資金問題。集團擬將聘請外部顧問與境外債權人共同探討各種可行方案,尋求相關債務的整體解決方案,集團亦將保持項目穩定營運以及銷售和回款力度,從而盡最大努力保護所有利益相關方的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.